<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00483067</url>
  </required_header>
  <id_info>
    <org_study_id>DM97-232</org_study_id>
    <nct_id>NCT00483067</nct_id>
  </id_info>
  <brief_title>2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)</brief_title>
  <official_title>Phase II Study: 2-Chlorodeoxyadenosine (2-CdA) and Cytarabine (Ara-C) in Idiopathic Hypereosinophilic Syndrome (HES)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
        1. To determine the response rate, progression-free survival (PFS) and overall survival of&#xD;
           patients who receive 2-CdA + Ara-C.&#xD;
&#xD;
        2. To examine if there is any clonality in the cytokine expression of helper T cells or&#xD;
           cytokine receptor expression of eosinophils.&#xD;
&#xD;
        3. To determine the effect of 2-CdA on accumulation of Ara-C triphosphate in eosinophils.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before the study begins, patients will have a physical exam, blood tests, and urine tests.&#xD;
      Women will have a pregnancy test. A bone marrow sample will be taken. This is done with a&#xD;
      large needle. Heart tests and an MRI scan of the brain will be done if there is a suspicion&#xD;
      of disease in the heart or central nervous system.&#xD;
&#xD;
      Patients in this study must have a catheter (thin tube) placed in a vein in the arm or under&#xD;
      the collarbone. This tube will be left in place throughout the study. 2-CdA (Cladribine) will&#xD;
      be given through the catheter 24 hours a day on days 2 to 6. Ara-C (Cytarabine) will be given&#xD;
      through the catheter over 2 hours on days 1, 3, 4, 5, and 6. Starting on day 9, patients will&#xD;
      inject G-CSF under their skin once a day; G-CSF helps blood counts return to normal.&#xD;
      Treatment will be given on an inpatient or outpatient basis. The first course is normally&#xD;
      done inpatient.&#xD;
&#xD;
      During the study, patients will have blood tests daily during the first week and every other&#xD;
      day after that. Bone marrow samples will be taken on days 14, 21, and 28. Further bone marrow&#xD;
      samples may be necessary to evaluate response. Heart tests and MRI scans of the brain may be&#xD;
      done.&#xD;
&#xD;
      This is an investigational study. G-CSF, 2-CdA, and Cytarabine are approved by the FDA for&#xD;
      treatment of cancer. Up to 40 patients will take part in this study. Patients will be treated&#xD;
      at M. D. Anderson or other centers. A total of 40 people will take part in this study. About&#xD;
      1 patient every 3 months will be enrolled at M. D. Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1998</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Outcomes at 6 Weeks</measure>
    <time_frame>Baseline to 6 weeks timepoint (day 42)</time_frame>
    <description>Patient outcomes defined at 6 weeks as Complete Remission (CR), absolute eosinophil count less than 1,500/mm3 and less than 5% of eosinophilic infiltrates in the bone marrow; and PR (partial response) defined as major clinical improvement without meeting the criteria specified for CR including an improvement in performance status to Zubrod's 0 or 1 along with clearance of clinical signs and symptoms of disease that are present at baseline.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>2-CdA + Ara-C + G-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2-CdA 12 mg/m^2/day by vein (IV) Continuous Infusion and Ara-C 1 gm/m^2/day IV for 5 Days with G-CSF 5 mcg/kg/day subcutaneously starting Day 9</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2-CdA</intervention_name>
    <description>12 mg/m^2/day by vein (IV) Continuous Infusion x 5 Days</description>
    <arm_group_label>2-CdA + Ara-C + G-CSF</arm_group_label>
    <other_name>2-Chlorodeoxyadenosine</other_name>
    <other_name>Cladribine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ara-C</intervention_name>
    <description>1 gm/m^2/day IV Over 2 Hours x 5 Days</description>
    <arm_group_label>2-CdA + Ara-C + G-CSF</arm_group_label>
    <other_name>Cytarabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF (Granulocyte colony-stimulating factor)</intervention_name>
    <description>5 mcg/kg/day given under the skin (subcutaneously) starting Day 9</description>
    <arm_group_label>2-CdA + Ara-C + G-CSF</arm_group_label>
    <other_name>Filgrastim</other_name>
    <other_name>Neupogen</other_name>
    <other_name>Granulocyte colony-stimulating factor</other_name>
    <other_name>GCSF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient must have diagnosis of idiopathic HES, defined as (1) no recent history of&#xD;
             allergic reaction or parasitic infection; (2) sustained (&gt; 6 months) hypereosinophilia&#xD;
             (1,500/mm^3); and (3) signs or symptoms of organ involvement.&#xD;
&#xD;
          2. Age less than 76 years old.&#xD;
&#xD;
          3. Patient is not pregnant.&#xD;
&#xD;
          4. Zubrod performance status &lt; 3.&#xD;
&#xD;
          5. Life expectancy is not severely limited by concomitant illness.&#xD;
&#xD;
          6. Serum creatinine &lt; 2 mg/dL.&#xD;
&#xD;
          7. Serum bilirubin &lt; 2 times upper limit of normal (2 mg/dL).&#xD;
&#xD;
          8. Alanine aminotransferase (SGPT) &lt; 2 times upper limit of normal (112 IU/L).&#xD;
&#xD;
          9. Participant has completed the informed consent process, understands the&#xD;
             investigational nature of the study, agrees to participate, and has signed the&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of chronic active hepatitis or cirrhosis, and &gt; 1 month from prior episode of&#xD;
             hepatitis.&#xD;
&#xD;
          2. Presence of an active infection.&#xD;
&#xD;
          3. HIV positive.&#xD;
&#xD;
          4. Has eosinophilic leukemia (defined by presence of clonal cytogenetic abnormalities).&#xD;
&#xD;
          5. Recent history of parasite infection.&#xD;
&#xD;
          6. Recent history of allergic reaction.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Andreeff, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.T.M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>June 5, 2007</study_first_submitted>
  <study_first_submitted_qc>June 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2007</study_first_posted>
  <last_update_submitted>August 1, 2012</last_update_submitted>
  <last_update_submitted_qc>August 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idiopathic Hypereosinophilic Syndrome</keyword>
  <keyword>Leukemia</keyword>
  <keyword>2-Chlorodeoxyadenosine</keyword>
  <keyword>Cladribine</keyword>
  <keyword>Cytarabine</keyword>
  <keyword>Ara-C</keyword>
  <keyword>2-CdA</keyword>
  <keyword>G-CSF</keyword>
  <keyword>HES</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypereosinophilic Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Cladribine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

